Enlivex Doses First U.S. Patient in Phase 2b Trial for Knee Osteoarthritis Treatment
Event summary
- Enlivex dosed the first U.S. patient in its Phase 2b trial for Allocetra™, targeting moderate-to-severe knee osteoarthritis.
- The global trial, also enrolling patients in Denmark and Poland, follows FDA IND clearance in March 2026 and DKMA approval in April 2026.
- Key endpoints include pain and physical function improvements, with data expected at three- and six-month intervals post-treatment.
- Knee osteoarthritis affects 32 million Americans today, with projections reaching 78 million by 2040.
The big picture
Enlivex’s Phase 2b trial initiation marks a critical step in addressing a significant unmet need in knee osteoarthritis, a condition with no approved disease-modifying therapies. The trial’s global scope and regulatory clearances underscore the company’s strategic push toward commercialization, as the aging population drives demand for innovative treatments. Success in this trial could position Allocetra™ as a leading therapeutic option in a rapidly expanding market.
What we're watching
- Clinical Efficacy
- Whether Allocetra™ can demonstrate durable, clinically meaningful pain and function improvements in the Phase 2b trial.
- Regulatory Momentum
- The pace at which Enlivex advances toward later-stage trials following positive Phase 2b data.
- Market Opportunity
- How Enlivex positions Allocetra™ in a knee osteoarthritis market lacking approved disease-modifying therapies.
Related topics